Last reviewed · How we verify
CJ-12420
At a glance
| Generic name | CJ-12420 |
|---|---|
| Also known as | Undecided |
| Sponsor | HK inno.N Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients (PHASE3)
- Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer (PHASE3)
- Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease (PHASE3)
- Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis (PHASE3)
- To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration (PHASE1)
- Pharmacodynamic Properties of CJ-12420 on Evening Dosing (PHASE1)
- To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration (PHASE1)
- A Study to Compare the Pharmacokinetic Characteristics of CJ-12420 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CJ-12420 CI brief — competitive landscape report
- CJ-12420 updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI